Ingersoll Rand raises 2026 revenue growth outlook to 4.5%-6.5% while expecting adjusted EPS near the high end of $3.45-$3.57

Earnings Call Insights: Ingersoll Rand (IR) Q2 2026

MANAGEMENT VIEW

* CEO Vicente Reynal said results reflected “continued strong execution and improved demand momentum,” citing “organic order growth of 2%, organic revenue growth of 4% and adjusted EPS growth of 7%,” and added, “we are raising our full year revenue guidance and expect adjusted EPS to land towards the higher end of our previously communicated range.”
* Reynal highlighted M&A and aftermarket mix, saying the company announced “the closing of one acquisition and the signing of another,” and emphasized that “both acquisitions strengthened our aftermarket capabilities.”
* Quote (Senior VP & CFO Vikram Kini): “Orders finished just over $2 billion, up 5% year-over-year with organic orders up 2%... Revenue grew 9% year-over-year to approximately $2 billion... Adjusted EPS was $0.86 for the quarter, up 7% year-over-year.”
* Quote (Senior VP & CFO Kini): “Free cash flow for the quarter was $269 million... Leverage remained at 1.7x... we reached an agreement on an initial $187.5 million recovery, with certain insurers on the RWI claim... related to the ILC Dover transaction.”

OUTLOOK

* Management updated full-year expectations, with Reynal saying, “we now expect revenue growth of 4.5% to 6.5%,” and clarifying the components: “approximately 1% to 3% organic growth, approximately 2.5% growth from M&A, and approximately 1% growth from FX.”
* Reynal maintained profit and cash targets: “We’re maintaining our adjusted EBITDA guidance range of $2.13 billion to $2.19 billion... Adjusted EPS remains projected at $3.45 to $3.57... Free cash flow conversion is currently expected to remain approximately 95%.”
* Reynal added two upside items excluded from guidance: “our adjusted EBITDA and adjusted EPS ranges exclude any benefit from IEEPA tariff refunds we expect in the second half of the year,” and CFO Kini said the remaining ILC Dover insurance cash recovery “is not reflected in our free cash flow guidance,” which he described as “pure upside.”

FINANCIAL RESULTS

* CFO Kini described margin drivers, saying, “Adjusted EBITDA was $520 million... with an adjusted EBITDA margin of 25.4%,” and that the margin decline was driven by “inflationary pressures, particularly in China,” “continued investment,” and “higher corporate costs,” adding, “Unallocated corporate costs were $49 million in the quarter versus $34.6 million a year ago.”
* Kini framed second-half margin expectations as seasonal and operational, stating, “the margin ramp in the back half of the year is normal course for us,” and he tied Q2 corporate cost pressure to a specific item: “The higher corporate costs were largely driven by year-to-date true-up of management incentive costs... which we do not expect to recur at this level in the back half of the year.”

Q&A

* Michael Halloran, Baird: Asked about short-/medium-cycle momentum and phasing; CEO Reynal: “Americas... has been the strongest,” while EMEA weakness was “timing rather than demand,” and he said July showed “double-digit order growth.”
* Halloran, Baird: Asked if long-cycle pushouts are easing; CEO Reynal: “we’re seeing better momentum on the long-cycle project.”
* Jeffrey Sprague, Vertical Research: Asked what’s driving long-cycle releases; CEO Reynal: “as power prices have moved up, the payback on replacing an older, less efficient machine is getting shorter.”
* Sprague, Vertical Research: Asked whether higher organic revenue guide is price or volume; CFO Kini: “it’s the volumes... the incremental 1% organic for the full year is really volume driven.”
* Nigel Coe, Wolfe Research: Asked if July order growth was organic and backlog impact; CEO Reynal: “organic is low double digit to mid-teens,” and CFO Kini: “building the backlog out for 2027.”
* Coe, Wolfe Research: Asked whether margin weakness was broader than China; CEO Reynal: “it’s really confined to China.”
* Robert Wertheimer, Melius: Asked Life Sciences market characterization; CEO Reynal pointed to biopharma, saying, “the exposure that we continue to have to GLP-1 is very strong.”
* Nathan Jones, Stifel: Asked quote-to-order timing and China portfolio actions; CEO Reynal: “nothing dramatically significant” on quote-to-order, and on China pricing, “it is definitely more transient.”
* Andrew Kaplowitz, Citi: Asked Precision Technologies durability and M&A cadence; CEO Reynal said PST is “getting back” to “mid-30 EBITDA,” and said the funnel is “very healthy... 11 transactions under LOI.”
* Christopher Snyder, Morgan Stanley: Asked drivers of back-half margin ramp; CFO Kini cited “better price realization,” normalization of “incentive compensation true-up,” and “productivity.”
* Amit Mehrotra, UBS: Asked whether July was idiosyncratic and about distributor behavior; CFO Kini said July shows long-cycle health but “we’re not necessarily implying” that level persists, and CEO Reynal said distributors “don’t typically hold inventory.”
* Nicole DeBlase, Deutsche Bank: Asked pricing dynamics in the Americas and PST margin outlook; CEO Reynal said pricing outside China was “fairly stable,” and CFO Kini said PST could be “in the 32% type range.”
* Andrew Buscaglia, BNP Paribas: Asked valuations and AI/infrastructure exposure; CEO Reynal said LOIs are “bolt-on... low double-digit pre-synergy multiple,” and linked products to “power generation and electricity infrastructure” and “closed-loop systems in data centers.”

SENTIMENT ANALYSIS

* Analysts’ tone was slightly positive, concentrating on July order strength, China pricing, and the magnitude/credibility of the back-half margin ramp, including caution about sustainability (e.g., UBS questioning whether July was “idiosyncratic”).
* Management’s tone was slightly positive in prepared remarks and measured in Q&A, repeatedly attributing order softness to timing and emphasizing confidence and normalization (e.g., “it’s really confined to China,” “more transient,” and “normal course” margin ramp).
* Versus the prior quarter, management focused less on tariffs/Middle East disruptions and more on order inflection and raised revenue guidance, while analyst questions shifted toward verifying July’s quality and the mechanics of margin recovery.

QUARTER-OVER-QUARTER COMPARISON

* Guidance language changed from Q1 “reaffirming our full year guidance” to Q2 “updating our full year guidance,” with revenue growth raised to “4.5% to 6.5%,” while adjusted EBITDA and adjusted EPS ranges were maintained.
* Q1 discussed delayed orders tied to “the conflict in the Middle East,” while Q2 emphasized Europe project timing and a stronger start to Q3, with Reynal saying July delivered “double-digit order growth.”
* Q2 introduced new capital allocation items not emphasized in Q1: Moody’s “one-notch upgrade” and the ILC Dover-related “initial $187.5 million recovery,” alongside two new acquisitions (Lone Star Blowers closed; Fai Filtri signed).

RISKS AND CONCERNS

* CFO Kini cited “inflationary pressures, particularly in China,” and Reynal acknowledged China remains “the most challenged market from a pricing perspective,” while maintaining the view that pricing pressure is “transient.”
* Management flagged timing risk in large projects, with Kini noting book-to-bill was “slightly lower... primarily reflecting the delayed timing of several large project orders,” while also stating expectations that longer-cycle projects “recover in the back half of the year.”

FINAL TAKEAWAY

Management framed Q2 as a quarter of improving demand and execution, paired with a higher full-year revenue growth outlook while keeping adjusted EBITDA and adjusted EPS ranges intact and pointing to results “near the high end” of the EPS range. The call centered on July’s low double-digit organic order growth, China-specific price/inflation margin pressure, and a normal back-half margin ramp supported by pricing realization, productivity, and nonrecurring incentive-cost true-ups, alongside incremental capital allocation capacity from bolt-on M&A and an ILC Dover insurance recovery excluded from adjusted earnings and cash guidance.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/ir/earnings/transcripts]

MORE ON INGERSOLL-RAND

* Ingersoll Rand Inc. (IR) Q2 2026 Earnings Call Transcript [https://seekingalpha.com/article/4928677-ingersoll-rand-inc-ir-q2-2026-earnings-call-transcript]
* Ingersoll Rand Inc. 2026 Q2 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4928621-ingersoll-rand-inc-2026-q2-results-earnings-call-presentation]
* Ingersoll Rand Is Slightly More Interesting Now (Rating Upgrade) [https://seekingalpha.com/article/4914996-ingersoll-rand-stock-slightly-more-interesting-now-rating-upgrade]
* Ingersoll Rand slips as revenue outlook rises but earnings forecast is steady [https://seekingalpha.com/news/4622256-ingersoll-rand-slips-as-raised-outlook-trails-wall-street-expectations]
* Ingersoll-Rand Non-GAAP EPS of $0.86 beats by $0.03, revenue of $2.05B beats by $90M [https://seekingalpha.com/news/4622115-ingersoll-rand-non-gaap-eps-of-0_86-beats-by-0_03-revenue-of-2_05b-beats-by-90m]